标题/作者	年份
The lung microenvironment: an important regulator of tumour growth and metastasis NK Altorki, GJ Markowitz, D Gao, JL Port, A Saxena, B Stiles, T McGraw, ... Nature Reviews Cancer 19 (1), 9-31	2019
Commensal microbiota promote lung cancer development via γδ T cells C Jin, GK Lagoudas, C Zhao, S Bullman, A Bhutkar, B Hu, S Ameh, ... Cell 176 (5), 998-1013. e16	2019
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer M Yuan, LL Huang, JH Chen, J Wu, Q Xu Signal transduction and targeted therapy 4 (1), 61	2019
Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma MA Gillette, S Satpathy, S Cao, SM Dhanasekaran, SV Vasaikar, K Krug, ... Cell 182 (1), 200-225. e35	2020
Bone metastases RE Coleman, J Brown, I Holen Abeloff's Clinical Oncology, 809-830. e3	2020
Current approaches to the management of brain metastases JH Suh, R Kotecha, ST Chao, MS Ahluwalia, A Sahgal, EL Chang Nature reviews Clinical oncology 17 (5), 279-299	2020
Integrative proteomic characterization of human lung adenocarcinoma JY Xu, C Zhang, X Wang, L Zhai, Y Ma, Y Mao, K Qian, C Sun, Z Liu, ... Cell 182 (1), 245-261. e17	2020
circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity B Li, L Zhu, C Lu, C Wang, H Wang, H Jin, X Ma, Z Cheng, C Yu, S Wang, ... Nature communications 12 (1), 295	2021
Targeted therapy and checkpoint immunotherapy in lung cancer R Ruiz-Cordero, WP Devine Surgical pathology clinics 13 (1), 17-33	2020
Liquid biopsy-based biomarkers of treatment response and resistance E Kilgour, DG Rothwell, G Brady, C Dive Cancer cell 37 (4), 485-495	2020
Toward personalized treatment approaches for non-small-cell lung cancer M Wang, RS Herbst, C Boshoff Nature medicine 27 (8), 1345-1356	2021
Immune evasion before tumour invasion in early lung squamous carcinogenesis C Mascaux, M Angelova, A Vasaturo, J Beane, K Hijazi, G Anthoine, ... Nature 571 (7766), 570-575	2019
Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives EN Imyanitov, AG Iyevleva, EV Levchenko Critical reviews in oncology/hematology 157, 103194	2021
Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer F Wu, J Fan, Y He, A Xiong, J Yu, Y Li, Y Zhang, W Zhao, F Zhou, W Li, ... Nature communications 12 (1), 2540	2021
Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer J Sun, Z Zhang, S Bao, C Yan, P Hou, N Wu, J Su, L Xu, M Zhou Journal for immunotherapy of cancer 8 (1)	2020
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial RS Herbst, HT Arkenau, R Santana-Davila, E Calvo, L Paz-Ares, ... The Lancet Oncology 20 (8), 1109-1123	2019
Molecular signature of subtypes of non-small-cell lung cancer by large-scale transcriptional profiling: identification of key modules and genes by weighted gene co-expression network analysis (WGCNA) M Niemira, F Collin, A Szalkowska, A Bielska, K Chwialkowska, J Reszec, ... Cancers 12 (1), 37	2019
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin R Woodhouse, M Li, J Hughes, D Delfosse, J Skoletsky, P Ma, W Meng, ... PloS one 15 (9), e0237802	2020
Abandoning the notion of non-small cell lung cancer V Relli, M Trerotola, E Guerra, S Alberti Trends in molecular medicine 25 (7), 585-594	2019
Tumor microenvironment-activatable Fe-doxorubicin preloaded amorphous CaCO3 nanoformulation triggers ferroptosis in target tumor cells CC Xue, MH Li, Y Zhao, J Zhou, Y Hu, KY Cai, Y Zhao, SH Yu, Z Luo Science advances 6 (18), eaax1346	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。